These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9769915

  • 1. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP.
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [Abstract] [Full Text] [Related]

  • 2. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA.
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [Abstract] [Full Text] [Related]

  • 5. [New approach in the research of analgesics and antihypertensive agents].
    Roques BP.
    Ann Pharm Fr; 1991 Jan; 49(6):317-26. PubMed ID: 1842170
    [Abstract] [Full Text] [Related]

  • 6. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I, Gonzalez W, el Amrani AI, Fournié-Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
    Gonzalez W, Beslot F, Laboulandine I, Fournié-Zaluski MC, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
    [Abstract] [Full Text] [Related]

  • 9. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ.
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [Abstract] [Full Text] [Related]

  • 10. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA.
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [Abstract] [Full Text] [Related]

  • 11. [Dual endopeptidase inhibitors--a new direction in the development of hypertensive agents].
    Horký K.
    Vnitr Lek; 2000 Mar; 46(3):148-51. PubMed ID: 11048516
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F, Leung R, Kladis A, James GM, Briscoe TA, Gorski TP, Campbell DJ.
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [Abstract] [Full Text] [Related]

  • 14. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, Michel JB, Roques BP.
    J Med Chem; 1996 Jun 21; 39(13):2594-608. PubMed ID: 8691458
    [Abstract] [Full Text] [Related]

  • 15. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B.
    Am J Hypertens; 2005 Dec 21; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [Abstract] [Full Text] [Related]

  • 16. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P, Jeng AY, Battistini B.
    J Cardiovasc Pharmacol; 2007 Sep 21; 50(3):247-56. PubMed ID: 17878751
    [Abstract] [Full Text] [Related]

  • 17. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM, Kemp PA, Brunner-Ferber F, Bennett T.
    Br J Pharmacol; 1997 Dec 21; 122(8):1687-93. PubMed ID: 9422815
    [Abstract] [Full Text] [Related]

  • 18. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME.
    J Hypertens; 2002 Apr 21; 20(4):707-14. PubMed ID: 11910307
    [Abstract] [Full Text] [Related]

  • 19. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR.
    J Pharmacol Exp Ther; 1996 Feb 21; 276(2):708-13. PubMed ID: 8632340
    [Abstract] [Full Text] [Related]

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 21; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.